A Single-center, Randomized Open-label, Single-dose, Parallel Group Study to Investigate the Relative Bioavailability of a High Concentration Liquid Formulation (Hclf) in Prefilled Syringes Versus the Reference Lyophilized Formulation (Lyof) of Gantenerumab Following Administration by Subcutaneous Injection in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2015
Price : $35 *
At a glance
- Drugs Gantenerumab (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Roche
- 03 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 21 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 12 May 2014 New trial record